Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1284-1294

  Chai, Dafei ^a   Yue, Yan ^a   Xu, Wei ^a   Dong, Chunsheng ^a   Xiong, Sidong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Adjuvant; AIM2; Chitosan; Coxsackievirus B3; Mucosal vaccine; SlgA; Viral myocarditis

Indexed keywords

ABSENT IN MELANOMA 2; APRIL PROTEIN; B CELL ACTIVATING FACTOR; CHITOSAN; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; SECRETORY IMMUNOGLOBULIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AIM2 PROTEIN, MOUSE; DNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; DENDRITIC CELL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENETIC TRANSFECTION; HEART CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MALE; MESENTERY LYMPH NODE; MOLECULAR WEIGHT; MOUSE; MUCOSAL IMMUNITY; MYOCARDITIS; NONHUMAN; PLASMID; PROTEIN BINDING; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SURVIVAL RATE; VIRUS MYOCARDITIS; VIRUS NEUTRALIZATION; VIRUS TITRATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; COXSACKIEVIRUS INFECTIONS; DRUG EFFECTS; ENTEROVIRUS B; HELA CELL LINE; IMMUNOLOGY; NOSE MUCOSA; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; CHITOSAN; COXSACKIEVIRUS INFECTIONS; DNA-BINDING PROTEINS; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; NASAL MUCOSA; TREATMENT OUTCOME; VACCINES, DNA;

EID: 84901428733     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28333     Document Type: Article

References (56)

1. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 1999; 99:1091-100; PMID:10051305; http://dx.doi.org/10.1161/01.CIR.99.8.1091
2. Maisch B, Ristiæ AD, Hufnagel G, Pankuweit S. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 2002; 11:112-22; PMID:11934603; http://dx.doi.org/10.1016/S1054-8807(01)00113-2
3. Huber SA, Born W, O'Brien R. Dual functions of murine gammadelta cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vgamma1+ and Vgamma4+ cells. Microbes Infect 2005; 7:537-43; PMID:15777711; http://dx.doi.org/10.1016/j.micinf.2004.12.011
4. Palmenberg AC. Proteolytic processing of picornaviral polyprotein. Annu Rev Microbiol 1990; 44:603-23; PMID:2252396; http://dx.doi.org/10.1146/annurev. mi.44.100190.003131
5. Tam PE. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 2006; 19:133-46; PMID:16817756; http://dx.doi.org/10.1089/vim.2006.19.133
6. Bailey JM, Tapprich WE. Structure of the 5′ nontranslated region of the coxsackievirus b3 genome: Chemical modification and comparative sequence analysis. J Virol 2007; 81:650-68; PMID:17079314; http://dx.doi.org/10.1128/JVI. 01327-06
7. Fohlman J, Pauksen K, Morein B, Bjare U, Ilbäck NG, Friman G. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis Suppl 1993; 88:103-8; PMID:8390713
8. Henke A, Wagner E, Whitton JL, Zell R, Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol 1998; 72:8327-31; PMID:9733878
9. Henke A, Zell R, Stelzner A. DNA vaccine-mediated immune responses in Coxsackie virus B3-infected mice. Antiviral Res 2001; 49:49-54; PMID:11166860; http://dx.doi.org/10.1016/S0166-3542(00)00132-7
10. Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 2004; 22:3603-12; PMID:15315839; http://dx.doi.org/10.1016/j.vaccine.2004.03.033
11. Dan M, Chantler JK. A genetically engineered attenuated coxsackievirus B3 strain protects mice against lethal infection. J Virol 2005; 79:9285-95; PMID:15994822; http://dx.doi.org/10.1128/JVI.79.14.9285-9295.2005
12. Kim JY, Jeon ES, Lim BK, Kim SM, Chung SK, Kim JM, Park SI, Jo I, Nam JH. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 2005; 23:1672-9; PMID:15705471; http://dx.doi.org/10.1016/j.vaccine.2004.10.008
13. Henke A, Jarasch N, Martin U, Wegert J, Wildner A, Zell R, Wutzler P. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease. Int J Med Microbiol 2008; 298:127-34; PMID:17897883; http://dx.doi.org/10.1016/j.ijmm.2007.08.010
14. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-8; PMID:19158675; http://dx.doi.org/10.1038/nature07725
15. Schattgen SA, Fitzgerald KA. The PYHIN protein family as mediators of host defenses. Immunol Rev 2011; 243:109-18; PMID:21884171; http://dx.doi.org/ 10.1111/j.1600-065X.2011.01053.x
16. Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, Hardy LL, Garceau V, Sweet MJ, Ross IL, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323:1057-60; PMID:19131592; http://dx.doi.org/10.1126/science.1169841
17. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458:509-13; PMID:19158676; http://dx.doi.org/10.1038/nature07710
18. Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCormick M, Huang L, McDermott E, et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 2010; 11:385-93; PMID:20351693; http://dx.doi.org/10.1038/ni.1859
19. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50; PMID:19302047; http://dx.doi.org/10.1146/annurev.immunol.021908.132612
20. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10:89-102; PMID:20081871; http://dx.doi.org/10.1038/nri2691
21. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010; 11:395-402; PMID:20351692; http://dx.doi.org/10.1038/ni.1864
22. Yue Y, Xu W, Hu L, Jiang Z, Xiong S. Enhanced resistance to coxsackievirus B3-induced myocarditis by intranasal co-immunization of lymphotactin gene encapsulated in chitosan particle. Virology 2009; 386:438-47; PMID:19233446; http://dx.doi.org/10.1016/j.virol.2009.01.029
23. Mora JR, Iwata M, Eksteen B, Song SY, Junt T, Senman B, Otipoby KL, Yokota A, Takeuchi H, Ricciardi-Castagnoli P, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006; 314:1157-60; PMID:17110582; http://dx.doi.org/10.1126/science.1132742
24. Massacand JC, Kaiser P, Ernst B, Tardivel A, Bürki K, Schneider P, Harris NL. Intestinal bacteria condition dendritic cells to promote IgA production. PLoS One 2008; 3:e2588; PMID:18596964; http://dx.doi.org/10.1371/ journal.pone.0002588
25. Tezuka H, Ohteki T. Regulation of intestinal homeostasis by dendritic cells. Immunol Rev 2010; 234:247-58; PMID:20193023; http://dx.doi.org/10.1111/j. 0105-2896.2009.00872.x
26. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343:1388-98; PMID:11070105; http://dx.doi.org/10.1056/NEJM200011093431908
27. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11(Suppl):S45-53; PMID:15812489; http://dx.doi.org/10.1038/nm1213
28. Kumar H, Kawai T, Akira S. Pathogen recognition in the innate immune response. Biochem J 2009; 420:1-16; PMID:19382893; http://dx.doi.org/10.1042/ BJ20090272
29. Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines 2012; 11:367-79; PMID:22380827; http://dx.doi.org/10.1586/erv.11.196
30. Kumagai Y, Akira S. [Role of PRRs in vaccine]. Nihon Rinsho 2011; 69:1541-6; PMID:21922750
31. Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 2012; 11:237-56; PMID:22309671; http://dx.doi.org/10.1586/erv.11.189
32. Lladser A, Mougiakakos D, Tufvesson H, Ligtenberg MA, Quest AF, Kiessling R, Ljungberg K. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Mol Ther 2011; 19:594-601; PMID:21157438; http://dx.doi.org/10.1038/mt.2010.268
33. Luke JM, Simon GG, Söderholm J, Errett JS, August JT, Gale M Jr., Hodgson CP, Williams JA. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011; 85:1370-83; PMID:21106745; http://dx.doi.org/10.1128/JVI.01250-10
34. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002; 76:6652-9; PMID:12050378; http://dx.doi.org/10.1128/JVI.76.13.6652- 6659.2002
35. Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 2006; 80:6218-24; PMID:16775309; http://dx.doi.org/10.1128/JVI.00121-06
36. Gao H, Yue Y, Hu L, Xu W, Xiong S. A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge. Vaccine 2009; 27:5313-9; PMID:19615961; http://dx.doi.org/10.1016/j.vaccine.2009.06.093
37. Yue Y, Xu W, Xiong S. Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant. DNA Cell Biol 2012; 31:479-88; PMID:21988406; http://dx.doi.org/10.1089/dna.2011.1367
38. Zhao F, Liu S, Zhang X, Yu J, Zeng T, Gu W, Cao X, Chen X, Wu Y. CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbits. Hum Vaccin Immunother 2013; 9:753-60; PMID:23563515; http://dx.doi.org/10.4161/hv.23064
39. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010; 62:12-27; PMID:19796660; http://dx.doi.org/10.1016/j.addr.2009.08.004
40. Lee MK, Chun SK, Choi WJ, Kim JK, Choi SH, Kim A, Oungbho K, Park JS, Ahn WS, Kim CK. The use of chitosan as a condensing agent to enhance emulsion-mediated gene transfer. Biomaterials 2005; 26:2147-56; PMID:15576190; http://dx.doi.org/10.1016/j.biomaterials.2004.07.008
41. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 2006; 1:117-28; PMID:17722528; http://dx.doi.org/ 10.2147/nano.2006.1.2.117
42. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998; 15:1326-31; PMID:9755881; http://dx.doi.org/10.1023/A:1011929016601
43. Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999; 182:21-32; PMID:10332071; http://dx.doi.org/10.1016/S0378-5173(99)00030-7
44. Kumar MN, Muzzarelli RA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004; 104:6017-84; PMID:15584695; http://dx.doi.org/10.1021/cr030441b
45. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010; 56:290-9; PMID:19788905; http://dx.doi.org/10.1016/j. yrtph.2009.09.015
46. Dass CR, Choong PF. Chitosan-mediated orally delivered nucleic acids: a gutful of gene therapy. J Drug Target 2008; 16:257-61; PMID:18446603; http://dx.doi.org/10.1080/10611860801900801
47. Wang X, Zhang X, Kang Y, Jin H, Du X, Zhao G, Yu Y, Li J, Su B, Huang C, et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 2008; 26:5135-44; PMID:18462848; http://dx.doi.org/10.1016/j.vaccine.2008.03.088
48. Mantis NJ, Rol N, Corthésy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011; 4:603-11; PMID:21975936; http://dx.doi.org/10.1038/mi.2011.41
49. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26:812-26; PMID:17570691; http://dx.doi.org/10.1016/j.immuni.2007.04.014
50. Brandtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest 2010; 39:303-55; PMID:20450282; http://dx.doi.org/10. 3109/08820131003680369
51. Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, Boyaka PN, Okahashi N, Yamamoto M, Kiyono H, Bluethmann H, et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 1995; 155:4621-9; PMID:7594461
52. Beagley KW, Eldridge JH, Lee F, Kiyono H, Everson MP, Koopman WJ, Hirano T, Kishimoto T, McGhee JR. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 1989; 169:2133-48; PMID:2786548; http://dx.doi.org/10.1084/jem.169.6.2133
53. Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 1999; 162:122-8; PMID:9886377
54. Henke A, Huber S, Stelzner A, Whitton JL. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995; 69:6720-8; PMID:7474082
55. Rezkalla S, Kloner RA, Khatib G, Smith FE, Khatib R. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1988; 12:412-4; PMID:2839568; http://dx.doi.org/10.1016/0735-1097(88)90414-7
56. Capozzo AV, Ramírez K, Polo JM, Ulmer J, Barry EM, Levine MM, Pasetti MF. Neonatal immunization with a Sindbis virus-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies. J Immunol 2006; 176:5671-81; PMID:16622037